Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Needham Maintains Buy on Conmed, Raises Price Target to $129

Author: Benzinga Newsdesk | February 01, 2024 08:22am
Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and raises the price target from $119 to $129.

Posted In: CNMD

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist